Outcome comparison of integrated psycho-oncological care versus unstructured care-Results of a non-randomised open-label two-arm trial

被引:0
|
作者
Taylor, Katherine [1 ]
Singer, Susanne [1 ]
May, Melanie [2 ]
Durdu, Guelsemin [3 ]
Petermann-Meyer, Andrea [3 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, Mainz, Germany
[2] Allgemeine Ortskrankenkasse Gen Med Insurance Pla, Dusseldor, Germany
[3] Rhein Westfal TH Aachen, Med Fac, Eureg Comprehens Canc Ctr, Sect Psychooncol,Dept Hematol Oncol Hemostaseol &, Aachen, Germany
关键词
cancer; mental health; oncology; outpatient care; psycho-oncological care; PSYCHIATRIC MORBIDITY; CANCER; PREVALENCE; DISORDERS; DISTRESS;
D O I
10.1111/ecc.13127
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To compare patients' experiences with a systematic, integrated psycho-oncological care (IC) model to experiences with "care as usual" (CAU). Methods To improve patients' knowledge about psychosocial support options and to facilitate use, an IC model was developed by psycho-oncologists and a health insurance company and implemented in one German cancer care facility. Using a parallel, non-randomised design, these patients' experiences were compared to CAU patients. In 2015, both patient groups received questionnaires 6-12 months post-inpatient treatment. Main outcomes were awareness, use and opinion of psycho-oncological care (PC) and anxiety level (Generalized Anxiety Disorder Scale (GAD-7)). Results 228 patients (IC = 90; CAU = 138) participated (response rate 24%). More IC patients felt adequately informed about PC (63% vs. 46%, ORadj: 2.5 (CI: 1.3-4.8); p = 0.008). More IC patients recalled being offered various support options and had had at least one PC discussion (44% vs. 33%, ORadj of IC patient saying "yes" instead of "No, didn't want to" compared to a CAU patient: 0.4 (CI: 0.2-0.8); p = 0.01). More IC patients rated their care as good/excellent (49% vs. 38%, ORadj: 1.8 (CI: 0.7-4.1; p = 0.2)). Anxiety levels were similar (GAD-7 score>=10: IC 34% vs. CAU 28%; p = 0.4). Conclusion Structured psycho-oncological care had some positive results on the outcomes, but anxiety levels did not differ.
引用
收藏
页数:7
相关论文
共 13 条
  • [1] Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial
    Balata, Mahmoud
    Radbruch, Lukas
    Hesse, Michaela
    Westenfeld, Ralf
    Neukirchen, Martin
    Pfister, Roman
    Batzler, Yann-Nicolas
    Oeztuerk, Can
    Kavsur, Refik
    Tiyerili, Vedat
    Weltermann, Birgitta
    Poelsler, Robert
    Standl, Thomas
    Nickenig, Georg
    Becher, Marc Ulrich
    LANCET HEALTHY LONGEVITY, 2024, 5 (10):
  • [2] The diabetes community exercise programme plus usual care versus usual care in patients with type 2 diabetes: A randomised, two-arm, parallel, open-label trial
    Hale, L.
    Higgs, C.
    Gray, A. R.
    Mann, J.
    Mani, R.
    Sullivan, T.
    Terry, J.
    Keen, D.
    Stokes, T.
    ECLINICALMEDICINE, 2022, 46
  • [3] Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
    Fennell, Dean
    Griffiths, Daniel
    Eminton, Zina
    Morgan-Fox, Abigail
    Hill, Kayleigh
    Ewings, Sean
    Stuart, Charlotte
    Johnson, Lucy
    Mallard, Kim
    Nye, Mavis
    Darlison, Liz
    Dulloo, Sean
    Cave, Judith
    Luo, Jin-Li
    Taylor, Paul
    Spicer, Jake
    Poile, Charlotte
    Bzura, Aleksandra
    Griffiths, Gareth
    BMJ OPEN, 2023, 13 (11):
  • [4] Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial
    Khalafallah, Alhossain A.
    Yan, Carl
    Al-Badri, Raghad
    Robinson, Ella
    Kirkby, Brooke E.
    Ingram, Emily
    Gray, Zara
    Khelgi, Vinod
    Robertson, Iain K.
    Kirkby, Brian P.
    LANCET HAEMATOLOGY, 2016, 3 (09): : E415 - E425
  • [5] Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial
    Chen, Maohui
    Huang, Yizhou
    Zhang, Shuliang
    Zheng, Yixiong
    Zeng, Taidui
    Chen, Chun
    Zheng, Bin
    BMJ OPEN, 2024, 14 (02):
  • [6] The impact of COVID-19 on the interpretation of psycho-oncological support trial results: a quasi-experimental approach using the data from the new form of care "Integrated cross-sectoral psycho-oncology (nFC-isPO)"
    Hagemeier, Anna
    Adams, Anne
    Krieger, Theresia
    Salm, Sandra
    Cecon-Stabel, Natalia
    Dresen, Antje
    Hellmich, Martin
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [7] The impact of COVID-19 on the interpretation of psycho-oncological support trial results: a quasi-experimental approach using the data from the new form of care “Integrated cross-sectoral psycho-oncology (nFC-isPO)”
    Anna Hagemeier
    Anne Adams
    Theresia Krieger
    Sandra Salm
    Natalia Cecon-Stabel
    Antje Dresen
    Martin Hellmich
    BMC Health Services Research, 23
  • [8] Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial
    Smits, F. Jasmijn
    Henry, Anne Claire
    Besselink, Marc G.
    Busch, Olivier R.
    van Eijck, Casper H.
    Arntz, Mark
    Bollen, Thomas L.
    van Delden, Otto M.
    van den Heuvel, Daniel
    van der Leij, Christiaan
    van Lienden, Krijn P.
    Moelker, Adriaan
    Bonsing, Bert A.
    Rinkes, Inne H. Borel
    Bosscha, Koop
    van Dam, Ronald M.
    Derksen, Wouter J. M.
    den Dulk, Marcel
    Festen, Sebastiaan
    Koerkamp, Bas Groot
    de Haas, Robbert J.
    Hagendoorn, Jeroen
    van der Harst, Erwin
    de Hingh, Ignace H.
    Kazemier, Geert
    van der Kolk, Marion
    Liem, Mike
    Lips, Daan J.
    Luyer, Misha
    de Meijer, Vincent E.
    Mieog, J. Sven
    Nieuwenhuijs, Vincent B.
    Patijn, Gijs A.
    te Riele, Wouter W.
    Roos, Daphne
    Schreinemakers, Jennifer M.
    Stommel, Martijn W. J.
    Wit, Fennie
    Zonderhuis, Babs A.
    Daamen, Lois A.
    van Werkhoven, C. Henri
    Molenaar, I. Quintus
    van Santvoort, Hjalmar C.
    LANCET, 2022, 399 (10338) : 1867 - 1875
  • [9] Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
    Amaria, Rodabe N.
    Prieto, Peter A.
    Tetzlaff, Michael T.
    Reuben, Alexandre
    Andrews, Miles C.
    Ross, Merrick J.
    Glitza, Isabella C.
    Cormier, Janice
    Hwu, Wen-Jen
    Tawbi, Hussein A.
    Patel, Sapna P.
    Lee, Jeffrey E.
    Gersbenwaid, Jeffrey E.
    Spencer, Christine N.
    Gopalakrishnan, Vancheswaran
    Bassett, Roland
    Simpson, Lauren
    Mouton, Rosalind
    Hudgens, Courtney W.
    Zhao, Li
    Zhu, Haifeng
    Cooper, Zachary A.
    Wani, Khalida
    Lazar, Alexander
    Hwu, Patrick
    Diab, Adi
    Wong, Michael K.
    McQuade, Jennifer L.
    Royal, Richard
    Lucci, Anthony
    Burton, Elizabeth M.
    Reddy, Sangeetha
    Sharma, Padmanee
    Allison, James
    Futreal, Phillip A.
    Woodman, Scott E.
    Davies, Michael A.
    Wargo, Jennifer A.
    LANCET ONCOLOGY, 2018, 19 (02) : 181 - 193
  • [10] Therapy of genomic unstable solid tumours (WHO grade 3/4?in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial
    Wang, Ling
    Tang, Jiaxi
    Chen, Xia
    Zhao, Juan
    Tang, Wanyan
    Liao, Bin
    Nian, Weiqi
    BMJ OPEN, 2022, 12 (06):